Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022)

Roivant Sciences (ROIV) has disclosed Non-Current Deffered Revenue for 1 consecutive years, with $11.9 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Non-Current Deffered Revenue changed N/A year-over-year to $11.9 million, compared with a TTM value of $11.9 million through Sep 2022, changed N/A, and an annual FY2022 reading of $13.7 million, changed N/A over the prior year.
  • Non-Current Deffered Revenue was $11.9 million for Q3 2022 at Roivant Sciences, down from $13.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $13.7 million in Q1 2022 and bottomed at $11.9 million in Q3 2022.